Overview : 

I am doctorate in Biotechnology from Banaras Hindu University duration from 2005 to 2007. My doctoral thesis work was on tumor immunothepary performed at University of Tokushima, Japan. With my doctoral research background and enthusiasm I kept my research interest almost in the same stream at Center for Cellular & Molecular Biology (CCMB) as a post doctoral fellow in between 2008 to 2012 and worked on profiling of miRNAs of Breast and Leukemia cancer where we have made couple of patents and quite decent publications. Thereafter, my research interest is more inclined towards the clinical and patient application oriented. I have joined Global Hospitals, Hyderabad (2012 to 2014) as a Research Scientist in the project on isolation & differentiation of adipose derived stem cells into function cardiomyocytes. Interestingly we made significant achievement and that were evident with research publications n peer reviewed international journals. To deepen my research endeavor in the area of regenerative medicine I moved to KIMS foundation & Research Center (KFRC) in the year 2014 and continued working on stem cell based research as well as on other research quests pertaining to patients direct benefits (e.g. psoriasis, rheumatic arthritis, chronic wound healing, focal cortical dysplasia (FCD) and cancer biology etc.) in collaboration with KIMS hospitals clinicians.

Since then I am presently working at KIMS Foundation & Research Centre (KFRC) as Principal Scientist and having following research interest:

1. Exploring the potential of regenerative medicines in the management of incurable diseases such as Alzheimer’s, Diabetes, Epilepsy, Glioblastoma, Joint pain etc. Our collaborative work with KIMS Orthopedics department on Avascular Necrosis and Osteoarthritis has shown significant improvements when the combination of bone marrow concentrate with platelet rich plasma was given. We are in the process of getting permission from CDSCO to treat Peripheral Vascular Disease and others with use of autologus Heamtopoietic Stem Cells and Mesenchymal Stem Cells.
2. We are working on identification of specific molecular markers of neuro-disorders such as focal cortical dysplasia (FCD) and Epilepsy which is main result of FCD. In general, there are three pathological subtypes of cortical dysplasia (Type I, II and III). It is basically a common cause of drug-resistant epilepsy, often subjected to neurosurgery, with a suboptimal long-term outcome. Diagnosis and prognosis of focal cortical dysplasia are lacking and posing a major clinical challenge. Hence our effort to find out markers which will aid in diagnosis of types and subtypes of FCDs and help in disease management.
3. Finding out the role of miRNAs as biomarkers of Focal Cortical Dysplasia and utilizing them for therapeutics and diagnosis purpose. With my earlier experience and curiosity on miRNAs as an excellent candidate of being target for diagnosis and therapy in disease such as cancer. As per literature miRNAs has exhibited their participation in FCD manifestation too, hence our interest to understand their role and FCD is also mounting.

Education :

• Ph.D., Biotechnology, Banaras Hindu University, Varanasi, 2005-2007.
  Thesis: A study on the role of HM1.24 and IL-4delta2 on aspects of immunotherapeutic approaches against cancer.
• M.Sc., Biotechnology, University of Hyderabad, 2001-2003.

Awards & achievements :

• Research Associateship from DBT at CCMB, Hyderabad, 2011 – 2012.
• Research Fellowship from DBT at CCMB, Hyderabad, 2008 – 2011.
• Research Fellowship from University of Tokushima, Japan, 2006 – 2007.
• Junior Research Fellowship from DBT at BHU, Varanasi, 2005 – 2006.
• Qualified CSIR-NET lectureship 2004.
• Qualified JNU entrance for M.Sc. Biotech (all over India) 2001.

Research Experience :

• Developing protocol for stem cell isolation, propagation characterization and cryopreservation from different sources under cGMP norms.
• Hematopoietic and mesenchymal stem cell research and its secretome application in therapy for CLI, Scleroderma, Cerebral Palsy etc
• Mesenchymal stem cell differentiation into cardiomyocytes towards the regeneration of ischemic heart muscles and labeling of cardiomyocytes with SPION for invivo
• Identification of Biomarkers for diagnosis and therapy of breast cancer and leukemia.
• RNAi based breast cancer therapeutics using extensive cellular and molecular biology methods.
• Immunotherapeutics of cancer using dendritic cells, T-cells and cytokines.
• In Vivo studies using mice and rats.

Publication & Patents :

1. Differential host responses to COVID-19: Unraveling the complexity. VK Verma, R Yadav, SS Beevi, AS Mohod, S Mancharla, N Damodar, et al . Diagnostic Microbiology and Infectious Disease 109 (2), 116281

2. Impact of Pim1 mutations on the survival outcomes of patients with breast cancer: Insights from a clinical study. SS Beevi, K Anbrasu, VK Verma, NK Panchal, KK Kannepalli, et al. Human Gene, 201295

3. MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways. VK Verma, SS Beevi, RA Nair, A Kumar, R Kiran, LE Alexander, Cell Communication and Signaling 22 (1), 100, 2024

4. U18666A-induced cholesterol accumulation decreases tumor-derived exosomes load and modulates malignant transformation. SS Beevi, VK Verma, MOLECULAR CANCER THERAPEUTICS 22 (12), 2023

5. Impact of promoter regio n mutations of Pim-1 on c-Myc expression as well as survival in patient s with breast cancer. SS Beevi, K Anbrasu, KK Kannepalli, VK Verma, RR Pillarisetti, J Med Sci Res 11 (3), 186-193, 2023

6. Prognostic Significance of Systemic Cholesterol Profile in Patients with Breast Cancer. R Chowdary, RR Pillarisetti, VK Verma, R Korabathina, SS Beevi, 1*, 2022

7. DNMT3A Co-Mutation with SF3B1, ASXL1 and TET2 in Indian Patients with Myelodysplastic Syndrome (MDS). SS Beevi, R Yadav, VK Verma, RC Darapuneni, SG Reddy, S Paduval, Biochemistry and Molecular Biology 7 (1), 1-1, 2022

8. Computational and molecular dynamics simulation approach to analyze the impactof XPD gene mutation on protein stability and function. NK Panchal, A Bhale, VK Verma, SS Beevi. Molecular Simulation 46 (15), 1200-1219-9, 2020

9. MicroRNA Signatures in Blood or Bone Marrow Distinguish Subtypes of Pediatric Acute Lymphoblastic Leukemia. ARAN, VKV, SSEAERPPK Kumarb, Translational Oncology 13 (9)12, 2020

10. PCR amplifiable DNA from breast disease FFPE section for mutational analysis. NK Panchal, A Bhale, R Chowdary, VK Verma, SS Beevi. Journal of Biomolecular Techniques: JBT 31 (1), 1-8,2020

11. Efficacy of Intra-Articular Injection of Platelet Rich Plasma and Hyaluronic Acid in Early Knee Osteoarthritis – Case Series. Krishnaiah Kurapati,Kavitha Anbarasu,Vinod Kumar Verma, Syed Sultan Beevi. European Journal of Molecular & Clinical Medicine 5 (1), 30–36,12, 2018

12. Xeno-free autologous platelet rich plasma for chronic wound management–Case series. K Kurapati, PK GV, K Anbarasu, AK Vaggu, V Nanduri, SS Beevi, VK Verma. Wound medicine 20, 54-57, 2018

13. Environmental impact on the onset of hypertension-induced end-stage renal disease. KA Kavitha Anbarasu, VK Verma, SS Beevi, VS Reddy, International Journal of Environmental Health Research,Vol. 28, No. 5, 511-521 2018
14. Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients. U Chakravdhanula, K Anbarasu, VK Verma, SS Beevi. Dermatologic Therapy 29 (6), 446-450, 38, 2016

15. Signal regulatory protein alpha (SIRPA) and kinase domain receptor (KDR) are key expression markers in cardiac specific precursor selection from hADSCs, VK Verma, SS Beevi, T Debnath, U Shalini, SR Kamaraju, LK Kona, New Horizons in Translational Medicine 2 (4-5), 93-101,7,2015

16. RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models. NK Tangudu, VK Verma, TD Clemons, SS Beevi, T Hay, G Mahidhara, Molecular cancer therapeutics 14 (5), 1259-1269-34,2015

17. Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging.VK Verma, SR Kamaraju, R Kancherla, LK Kona, SS Beevi, T Debnath, International Journal of Nanomedicine, 711-726-34,2015

18. OncomiRdbB: a comprehensive database of microRNAs and their targets in breast cancer. R Khurana, VK Verma, A Rawoof, S Tiwari, RA Nair, G Mahidhara, BMC Bioinformatics 15 (1), 1-12-22, 2014

19. Biomarkers useful for detection of types, grades and stages of human breast cancer. KL Dinesh, VK Verma, RA Nair, J Prabhakar, J Kattoor. Council Of Scientific And Industrial Research WO 2013057567, A11, 2013

20. Effect of physical exercise on tumor growth regulating factors of tumor microenvironment: implications in exercise-dependent tumor growth retardation. VK Verma, V Singh, MP Singh, SM Singh. Immunopharmacology and immunotoxicology 31 (2), 274-282-48, 2009

21. Treadmill exercise-dependent tumor growth retardation in T-cell lymphoma-bearing host displays gender dimorphism.VK Verma, V Singh, MP Singh, SM Singh. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 18 10, 2009

22. Chimeric and humanized anti-HM1. 24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells, W Wang, Y Nishioka, S Ozaki, A Jalili, VK Verma, M Hanibuchi, S Abe, Lung cancer 63 (1), 23-31,28,2009

23. Efficient shoot regeneration in pigeon pea, Cajanus cajan (L) Millisp. using seedling petioles.T Srinivasan, VK VERMA, PB Kirti. Current science 86 (1), 30-32-25,2004